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Combination of TLR1/2 and 
TLR3 ligands enhances CD4+ 
T cell longevity and antibody 
responses by modulating type I IFN 
production
Bo Ryeong Lee1, Soo Kyung Jeong2, Byung Cheol Ahn2, Byeong-Jae Lee3, Sung Jae Shin4, 
Jung Sun Yum2 & Sang-Jun Ha1
Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccine 
efficacy, it remains unclear which combinations of TLR ligands are effective or what their underlying 
mechanisms may be. Here, we investigated the mechanism of action of L-pampo, a proprietary 
adjuvant composed of TLR1/2 and TLR3 ligands. L-pampo dramatically increased humoral immune 
responses against the tested target antigens, which was correlated with an increase in follicular 
helper T cells and the maintenance of antigen-specific CD4+ T cells. During the initial priming phase, 
in contrast to the induction of type I interferon (IFN) and pro-inflammatory cytokines stimulated by 
polyI:C, L-pampo showed a greatly diminished induction of type I IFN, but not of other cytokines, 
and remarkably attenuated IRF3 signaling, which appeared to be critical to L-pampo-mediated 
adjuvanticity. Collectively, our results demonstrate that the adjuvant L-pampo contributes to the 
promotion of antigen-specific antibodies and CD4+ T cell responses via a fine regulation of the TLR1/2 
and TLR3 signaling pathways, which may be helpful in the design of improved vaccines.
Toll-like receptor (TLR) ligands are widely studied as adjuvants, particularly in combination with subunit vac-
cines, because they modulate immune responses, thereby establishing a sufficient amount of protective immu-
nity1,2. In an effort to identify more efficacious adjuvants, specific combinations of TLR ligands have been found 
to be better than single-ligand adjuvants3,4. Some combinations of TLR ligands synergistically enhance both 
the magnitude and quality of the immune response, including the generation of follicular helper T (Tfh) cells, 
the survival of antigen-presenting cells (APCs), and the affinity of antibodies5,6. Indeed, when vaccinated with 
pathogen-specific antigens, the combinatorial use of TLR ligands was more effective in controlling bacterial and 
viral infections than single TLR ligands5–7. However, the underlying mechanism by which combinations of TLR 
ligands enhance the immune responses requires further investigation for rational vaccine design.
After vaccination, the maintenance of high frequencies of memory T cells is a critical parameter for maximiz-
ing protective efficacy. Upon boosting, pre-existing high frequencies of memory T cells correlate well with mem-
ory differentiation, whereas less pre-existing memory cells go through more cell divisions and become senescent8. 
To prevent erosion of the proliferative potential of memory T cells, an extensive mechanistic perspective into 
the maintenance of memory T cells is necessary. Despite the importance of CD4+ T cells in both humoral and 
cellular protective immunity, factors and adjuvants that control the maintenance of memory CD4+ T cells are not 
well-understood compared to those of memory CD8+ T cells9–15.
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Here, we investigate how TLR1/2 and TLR3 ligands synergize to enhance antigen-specific T and B cells. We 
have previously reported that L-pampo, a proprietary adjuvant composed of Pam3Csk4 (Pam3) and polyinosin-
ic:polycytidylic acid (polyI:C), induced a much stronger humoral immune response to surface antigens of hep-
atitis B virus (HBV) than aluminum hydroxide (alum)16. PolyI:C, a synthetic double-stranded RNA (dsRNA), is 
an agonist of TLR3 and RIG-I that predominantly produces type I interferon (IFN) via the TBK1-IRF3 axis and 
strongly polarizes T helper 1 (Th1) immunity17,18. Pam3, a synthetic bacterial lipoprotein, is a TLR1/2 agonist 
reported to produce pro-inflammatory cytokines such as IL-6 and IL-10 via the NFκ B signaling pathway and 
polarize T helper 2 (Th2) immunity19,20. When L-pampo is used as an adjuvant in a protein immunization sys-
tem, it contributes to the maintenance of antigen-specific CD4+ T cell responses by regulating the IRF signaling 
pathway and type I IFN production. The potent L-pampo-adjuvanted CD4+ T cell responses, after booster immu-
nization, led to the generation of multifunctional CD4+ T cells and class-switched antibodies correlating to the 
expansion of germinal center B (GC B) cells. Collectively, we propose that L-pampo adjuvanticity significantly 
modulates the innate cytokine environment and maintains antigen-specific CD4+ T cells during the memory 
phase, which leads to the expansion of functional CD4+ T cells, GC B cells and the enhanced production of 
class-switched antibodies, most likely amplified upon boosting.
Results
L-pampo adjuvanticity synergistically enhances antibody production and expands germinal 
center B cells. To validate the efficacy of L-pampo as an adjuvant, we immunized mice three times at 3-week 
intervals with ovalbumin protein (OVA) alone or together with polyI:C, Pam3, or L-pampo. Alum was used as a 
control adjuvant. From the 6th week after the first immunization, a synergistic enhancement of the OVA-specific 
IgG titer was observed in mice that received L-pampo as an adjuvant (Fig. 1a).
Antibody isotype analysis is one indicator of the type of immune responses21. A dominance of IgG1 indicates 
a Th2-type immunity, whereas a dominance of IgG2a, IgG2b, or IgG2c antibodies implies a Th1-type immunity. 
As expected, IgG1 was dominant in mice given alum or Pam3, but IgG2 (IgG2a, IgG2b, and IgG2c) was dominant 
in the polyI:C-treated group. The L-pampo-treated group showed the highest levels of both IgG1 and IgG2 among 
the experimental groups (Fig. 1b). The ratio of IgG2c to IgG1 in the L-pampo group was higher than that in the 
alum or Pam3 groups and slightly lower than that in the polyI:C group (Fig. 1c). In conclusion, the combination 
of polyI:C and Pam3 showed synergistic enhancement of both Th1-type and Th2-type OVA-specific antibodies.
Next, we tested the expansion of germinal center B (GC B) cells, which are closely related to antibody 
responses. A germinal center is a compartment within a B cell follicle in the secondary lymphoid tissues in which 
GC B cells go through functional maturation steps, such as somatic hypermutation (SHM) and B cell memory 
generation, which allow for tight regulation of protective humoral immunity22,23. Similar to what was observed 
with antibody production, a synergistic expansion of germinal center B cells was observed in mice that received 
OVA and L-pampo, indicating a better antibody quality (Fig. 1d).
L-pampo adjuvanticity modulates the antibody response against the HBV antigen toward a 
Th1-type response. To examine whether the adjuvant effect of L-pampo would also apply to a different 
protein antigen, L-HBsAg, which includes HBV surface antigens S and preS proteins, was used with the same 
series of adjuvants as described above. Similar to the increased OVA-specific antibody response by L-pampo, 
L-HBsAg-specific IgG production was the highest in the mice given the L-pampo adjuvant (Fig. 2a). In this sys-
tem, Pam3 strongly induced a substantial production of HBs-specific or PreS-specific antibodies with a relatively 
low IgG2c/IgG1 ratio, whereas polyI:C did not induce antibody titers as well as Pam3 but still had a higher IgG2c/
IgG1 ratio than Pam3 (Fig. 2a–c). When L-HBsAg was combined with L-pampo, the ratio of IgG2c/IgG1 was as 
high as it was when combined with polyI:C (Fig. 2c). The induction of high titers of Th1-polarized antibodies 
against L-HBsAg would be beneficial because Th1-type isotypes are closely related to cellular immunity, which is 
critical to defense against cell-residing viruses.
Interestingly, a synergistic expansion of GC B cells was observed in the L-pampo-adjuvanted group, which 
implies that L-pampo adjuvanticity most likely induces a better functional antibody response, such as the produc-
tion of antibodies with higher affinity, despite the similar antibody titers observed in Pam3 adjuvanticity (Fig. 2d).
Pam3 and L-pampo promote the expansion of Tfh cells in the periphery, but only L-pampo 
adjuvanticity prominently maintains OVA-specific CD4+ T cells during the memory phase. To 
dissect the underlying mechanism for the enhanced antibody responses by L-pampo, we analyzed OVA-specific 
CD4+ T cell responses over time, including the effector and memory phases. To monitor the responses, OT-II 
cells were adoptively transferred prior to OVA immunization. OT-II cells in the blood of each adjuvant group 
expanded well at the effector phase and gradually contracted until day 46 after immunization (Fig. 3a). However, 
OT-II cells from the L-pampo group expanded the most and remained in the blood at significantly high levels 
even at day 46 and in the spleen at day 48 (Fig. 3a,e).
To examine antigen-specific CD4+ T cell and B cell responses more closely, the lymphocytes in the spleens 
were analyzed at day 8 post-immunization. Tfh cells are a specialized subtype of CD4+ T cells used for B cell help; 
therefore, they are critical for enhancing antibody responses24. CXCR5 expression is a signature that enables 
Tfh to localize in the B cell zone and form germinal centers by interacting with cognate B cells25. A considerable 
expansion of PD-1+ CXCR5+ Tfh cells and GL7+ CXCR5+ germinal center-Tfh (GC-Tfh) cells was observed in 
mice immunized with OVA plus Pam3 or L-pampo (Fig. 3b,c). With regard to Th1 differentiation, OT-II cells 
from the polyI:C group had the highest frequency of IFN-γ + cells, but the number of IFN-γ + OT-II cells was 
generally similar among each adjuvant group (Fig. 3d). Taken together, our results indicate that both L-pampo 
and Pam3 adjuvanticity expands and polarizes more Tfh cells than the other adjuvants at the effector phase, but 
L-pampo is the only adjuvant that significantly supports the longevity of OVA-specific CD4+ T cells.
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At day 29 post-immunization, the highest titers of OVA-specific antibodies and isotypes, particularly the 
Th1-type, were observed in the mouse serum from the L-pampo group (Fig. 3f,g). This could be related to the 
high number of OT-II cells in the L-pampo group. That is, OVA-specific CD4+ T cells from the L-pampo group 
were significantly maintained and thus likely supported antibody responses well.
L-pampo attenuates type I IFN production and IRF signaling induced by polyI:C but amplifies 
AP-1/NFκB signaling. To investigate the factors that support the differentiation and maintenance of CD4+ 
T cells, we analyzed the effect of L-pampo on the in vivo profiles of secreted cytokines and signaling molecules in 
the TLR pathway in the first 24 hours, which could be a critical time point for the onset of T cell differentiation. 
As expected, polyI:C produced a substantial amount of IFN-α and IFN-γ , whereas Pam3 produced little IFN-α 
and IFN-γ but a significant amount of pro-inflammatory cytokines such as TNF-α in both the serum and the 
spleen (Fig. 4a). Surprisingly, when polyI:C and Pam3 were combined (L-pampo), a significantly attenuated level 
Figure 1. L-pampo is a potent adjuvant that enhances the production of OVA-specific antibodies and 
expands germinal center B cells upon tertiary immunization with OVA. Naïve B6 mice were immunized 
with 100 μ g of OVA alone or in combination with alum, polyI:C, Pam3, or L-pampo as adjuvants, followed by 
the same immunization 3 and 6 weeks after the first immunization. (a) Individual mouse sera were isolated 
at the indicated time points after the first immunization, and OVA-specific IgG levels were measured with 
an ELISA. (b) At the 7th week, the indicated isotypes were measured with an ELISA. (c) The relative ratios of 
OVA-specific IgG2c to IgG1 were calculated as an indirect measure of T helper 1 (Th1) and Th2 type immune 
responses. (d) Seven weeks after the first immunization, splenocytes from each mouse were analyzed by flow 
cytometry. Representative FACS plots and the frequencies and numbers of germinal center B cells (gated as 
live B220+ CD19+ GL-7+ PNA+ lymphocytes) in the spleen of each mouse are shown. Data are represented as 
the mean ± SEM with each dot indicating one mouse (n = 5). The data are representative of two independent 
experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 2. L-pampo is a potent adjuvant that modulates the mode of antibody responses and expands 
germinal center B cells upon tertiary immunization with the HBV surface protein. Naïve B6 mice were 
immunized with 40 μ g of L-HBsAg, an HBV surface protein, alone or in combination with alum, polyI:C, Pam3, 
or L-pampo as adjuvants, followed by the same immunization 3 and 6 weeks after the first immunization. (a) 
Individual mouse sera were isolated at the indicated time points after the first immunization, and HBs- or PreS-
specific IgG was measured by an ELISA. (b) At 7 weeks, the indicated isotypes were measured by an ELISA. 
(c) The relative ratios of HBs- or PreS-specific IgG2c to IgG1 were calculated. (d) Seven weeks after the first 
immunization, splenocytes were analyzed by flow cytometry. Representative FACS plots and the frequencies 
and numbers of germinal center B cells (gated as live B220+ CD19+ GL-7+ PNA+ lymphocytes) in the spleen 
are shown. Data are represented as the mean ± SEM with each dot indicating one mouse (n = 4). *p < 0.05; 
**p < 0.01; ***p < 0.001.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:32526 | DOI: 10.1038/srep32526
of IFN-α but a similar amount of IFN-γ and TNF-α were observed in the serum and spleen compared to the 
amounts in the polyI:C group (Fig. 4a).
To verify the L-pampo-mediated attenuation of type I IFN production in TLR signaling molecules, CD11c+ 
conventional dendritic cells (cDCs) enriched in vivo were isolated and treated ex vivo with polyI:C, Pam3, or 
L-pampo for 0.5, 1, or 3 h. The up-regulation of phosphorylated TBK1 and IRF3 observed in polyI:C-treated 
cDCs was significantly attenuated after 3 h of stimulation with L-pampo, reaching levels observed in the atten-
uated IFN-α production above (Fig. 4a,b). Likewise, a similar effect was observed in a macrophage cell line, 
Raw264.7, confirming that the activation of the TBK1-IRF3-type I IFN axis by polyI:C is considerably attenuated 
by Pam3 in L-pampo-treated Raw264.7 (Fig. 4c). However, signaling molecules such as phosphorylated JNK, Iκ 
B, and p38 that convergent to activate NFκ B or AP-1 were generally amplified in both cDCs and Raw264.7 cells 
when polyI:C and Pam3 were combined as L-pampo (Fig. 4c). Thus, L-pampo modulates TLR signaling pathways 
triggered by polyI:C or Pam3 alone, thereby leading to a different innate cytokine environment in which the pro-
duction of type I IFNs is selectively attenuated.
It has been well understood that adjuvants promote the maturation of APCs by up-regulating co-stimulatory 
molecules such as CD40, CD80, or CD86 together with major histocompatibility complex (MHC) molecules, 
leading to a better priming of T cells3,26. In this regard, we analyzed the subtype-specific maturation status of DCs 
Figure 3. Pam3 and L-pampo promote the expansion of follicular helper T cells in the periphery, but only 
L-pampo adjuvanticity prominently maintains OVA-specific CD4+ T cells during the memory phase. 
Naïve Ly5.2+ B6/J mice were injected with Ly5.1+ OT-II cells (5 × 105 cells each) before the immunization and 
immunized with 100 μ g of OVA alone or in combination with alum, polyI:C, Pam3, or L-pampo as adjuvants. 
(a) Mouse PBMCs were isolated from the blood, and the frequency of the transferred OT-II cells (CD4+ 
CD44+ Ly5.1+) among CD4+ T cells was analyzed kinetically by flow cytometry at the indicated time points 
after immunization. (b–d) Eight days after the immunization, splenocytes were isolated and analyzed by flow 
cytometry. (b) Representative FACS plots and the frequencies and numbers of the transferred OT-II cells among 
CD4+ T cells (gated as CD4+ CD44+ Ly5.1+). (c) Representative FACS plots and the frequencies of PD-1+ 
CXCR5+ follicular helper T cells (Tfh) or GL-7+ CXCR5+ germinal center Tfh (GC-Tfh). (d) Concatenated 
FACS plots of cytokine-producing OT-II cells and the frequencies and numbers of IFN-γ + cells among the 
OT-II cells. (e) Forty-eight days after immunization, splenocytes were isolated and analyzed by flow cytometry. 
Representative FACS plots and the frequencies and numbers of the transferred OT-II (CD4+ CD44+ Ly5.1+) 
cells among CD4+ T cells. (f,g) Mouse serum was isolated at the indicated time points, and OVA-specific IgG 
(f) and the indicated isotypes at day 29 (g) were determined by an ELISA. The data are represented as the 
mean ± SEM with each dot indicating one mouse (n = 3–4). The data are representative of two independent 
experiments. *p < 0.05; **p < 0.01; ***p < 0.001.
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Figure 4. L-pampo attenuates type I IFN secretion in vivo and polyI:C-induced IRF3 signaling. (a) Naïve 
B6 mice were immunized with 100 μ g of OVA alone or in combination with alum, polyI:C, Pam3, or L-pampo as 
adjuvants. The spleen and serum of each immunized mouse were collected at the indicated time points, and the 
levels of IFN-γ , TNF-α , and IFN-α were determined using a multiplex analysis. The level of cytokines detected 
in the spleen supernatant was divided by the weight (g) of the spleen of that mouse. n.d., not detected. The data 
are represented as the mean ± SEM (n = 3); *p < 0.05; **p < 0.01; ***p < 0.001. (b,c) CD11c+ conventional 
dendritic cells (cDCs) isolated from flt3L-expressing-B16F10-injected mice (left column) or cells from the 
mouse macrophage cell line Raw264.7 (right column) were treated with polyI:C, Pam3, or L-pampo for the 
indicated time; western blots were performed to quantify proteins in the TBK1-IRF3 signaling pathway (b) or 
the AP-1/NFκ B signaling pathway (c). The data are representative of two independent experiments.
www.nature.com/scientificreports/
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by profiling the expression of co-stimulatory molecules and MHC molecules during the first 24 h after immu-
nization (Fig. S1a). Indeed, the co-injection of polyI:C, Pam3, or L-pampo along with OVA induced a more 
potent upregulation of CD86 in lymphoid and myeloid DCs than an OVA immunization alone. The expressions 
of CD80, CD40, and MHC class II molecules were also slightly enhanced in lymphoid DCs in adjuvant-treated 
groups (Fig. S1b). However, no enhanced expression of such molecules was observed in DCs in the L-pampo 
group compared to the polyI:C or Pam3 group (Fig. S1b).
L-pampo has the ability to generate a high quantity and quality of memory CD4+ T cells. To 
analyze the boosting efficacy of each adjuvant, the expansion and cytokine-producing abilities of OVA-specific 
CD4+ T cells were examined after the boost. Notably, the expansion of OT-II cells in the blood was the most 
prominent in the L-pampo group (Fig. 5a). Compared to the other groups, the L-pampo group had the high-
est frequency and the most abundant numbers of OT-II cells in the spleen after the boost (Fig. 5b). Moreover, 
although the levels of IFN-γ produced (% IFN-γ + among OT-II cells) in the L-pampo group were comparable to 
those produced in the polyI:C group, the percentage of multi-cytokine-producing OT-II cells (TNF-α + IFN-γ + 
among IFN-γ + cells) was significantly higher than in the other groups (Fig. 5c,d).
The boost efficacy was far more amplified by the second boost. The spleens of the recipient mice were analyzed 
one week after the third immunization. OT-II cells from the L-pampo group expanded synergistically compared 
to those from the polyI:C or Pam3 groups (Fig. 5e). Moreover, the IFN-γ -producing capability of OT-II cells was 
higher in the L-pampo group than in the other groups, and their multi-cytokine-producing ability (TNF-α +  
IFN-γ + among IFN-γ + cells) was also superior to that observed in the other groups (Fig. 5f,g). Considering the 
number of OT-II cells in the L-pampo group and their ability to produce multi-cytokines together, the overall 
production of the cytokines should be much higher. This was verified by a cytokine ELISA of IFN-γ , IL-6, and 
Figure 5. L-pampo expands multi-cytokine-producing antigen-specific CD4+ T cells more synergistically 
as the number of boosts increases. Naïve Ly5.2+ B6/J mice were injected with Ly5.1+ OT-II T cells (5 × 105 
each) before the immunization, then immunized with 100 μ g of OVA alone or in combination with alum, 
polyI:C, Pam3, or L-pampo as adjuvants, followed by the same immunization at day 30 (a–d) or 3 or 6 weeks 
after the first immunization (e–h). (A) Mouse PBMCs were isolated from the blood, and the frequencies of the 
transferred OT-II cells (CD4+ CD44+ Ly5.1+) among CD4+ T cells were analyzed kinetically by flow cytometry 
at the indicated time points. (b–h) Six days after the secondary immunization (b–d) or 7 days after the tertiary 
immunization (e–h), splenocytes were isolated and analyzed by flow cytometry. (b,e) Representative FACS plots 
and the frequencies and numbers of the transferred OT-II cells (CD4+ CD44+ Ly5.1+) among CD4+ T cells are 
shown. (c,f) Representative (c) or concatenated (f) FACS plots and the frequencies and numbers of IFN-γ +- 
producing CD4+ T cells among total CD4+ T cells are shown. (d,g) Representative (d) or concatenated (g) 
FACS plots of cytokine-producing OT-II cells and the frequencies of IFN-γ + cells among the OT-II cells and 
of IFN-γ + TNF-α + cells among IFN-γ + OT-II cells and the IFN-γ expression levels of IFN-γ + OT-II cells were 
determined using the mean fluorescence intensity (MFI) of IFN-γ . (h) Splenocytes were stimulated ex vivo with 
OVA323–339 peptides. The levels of IFN-γ , IL-6, and TNF in the supernatants of the re-stimulated splenocytes 
were measured by a cytokine ELISA (left column). Splenocytes were analyzed for IFN-γ or IL-4 secretion by an 
ELISpot assay (right column). The data are represented as the mean ± SEM with each dot indicating one mouse 
(n = 4). *p < 0.05; **p < 0.01; ***p < 0.001.
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TNF secreted from splenocytes and by an ELISpot assay of IFN-γ - and IL-4-secreting cells among splenocytes, 
which were ex vivo stimulated with OVA323–339 peptides (Fig. 5h) or OVA (Fig. S2a,b).
The level of expansion of the transferred OVA-specific CD8+ T cells (OT-I cells) from the L-pampo group 
was a little lower than that of the polyI:C group (Fig. S3a), but their functional capability to produce IFN-γ and 
multi-cytokines was superior to the other groups, as determined by the frequency of TNF-α + IFN-γ + among 
IFN-γ + cells and their intensity of IFN-γ expression after ex vivo stimulation (Fig. S3b). The amount of IFN-γ 
and TNF-α secreted from the splenocytes and the spot numbers of IFN-γ -secreting splenocytes, when stimulated 
with the OVA257–264 peptide, appeared to be similar between the polyI:C and L-pampo groups, but IL-6 secretion 
was higher than in the L-pampo group than in the other groups (Fig. S3c,d). Therefore, L-pampo adjuvanticity 
appears to enhance the expansion of multi-functional antigen-specific T cells, particularly CD4+ T cells, com-
pared to polyI:C or Pam3 administered alone.
Discussion
In this study, we report an efficacious combination of TLR ligands that synergistically enhances the antibody 
responses against two different protein antigens. As a mechanism of action, we propose that the combination of 
polyI:C and Pam3 results in a cytokine environment that is distinct from the environment resulting from the use 
of polyI:C or Pam3 alone, exhibiting a prominent maintenance of antigen-specific CD4+ T cells during the mem-
ory phase. The expansion of functional CD4+ T cells is likely amplified during each round of boosting, leading 
to the significant expansion of GC B cells and the production of isotype-switched antibodies in mice immunized 
with OVA and L-pampo.
First, we examined the changes in a signaling pathway resulting from the combination of Pam3 and polyI:C. 
PolyI:C and Pam3 both inhibit and synergize together to form a unique cytokine environment. When poly-
I:C and Pam3 are combined, the robust phosphorylation of TBK1 and IRF3 by polyI:C was inhibited by Pam3, 
whereas that of NFκ B and AP-1 signaling molecules was synergistically enhanced, both in primary CD11c+ cells 
and in a macrophage cell line. These findings are consistent with a previous report that showed that the levels 
of some interferon-stimulated genes (ISGs) and ifn-b mRNA were reduced when mouse bone marrow-derived 
dendritic cells (BMDCs) were treated with polyI:C and Pam327. Mechanistically, the polyI:C-mediated induction 
of type I IFNs has been reported to be directly inhibited by TLR1/2 adaptor proteins such as MyD88 and MyD88 
adaptor-like (Mal) or negatively regulated by the NFκ B subunits RelB and cRel via transcriptional repressor pro-
tein YY1 in bone marrow-derived macrophages (BMDMs) and BMDCs28–31.
At the effector phase, we showed that the expansion of Tfh was higher in L-pampo- and Pam3-treated groups. 
Recently, it was shown that type I IFN acts as a repressor of signal transducer and activator of transcription 3 
(STAT3), thereby limiting Tfh differentiation in a virus infection model32. This report partially provides a link 
between the attenuated type I IFN production and expansion of Tfh. Because of the importance of Tfh in forming 
and supporting the GC response, the expansion of Tfh by L-pampo and Pam3 is thought to contribute to the 
enhancement of antibody titers and isotype-switching later.
Interestingly, what makes L-pampo different from Pam3 and other adjuvants is its ability to adequately 
maintain antigen-specific CD4+ T cells during the memory phase. Because factors affecting the maintenance of 
antigen-specific CD4+ T cells are relatively under-studied compared to those for CD8+ T cells, many questions 
remain as to whether the maintenance of antigen-specific CD4+ T cells is programmed when they are primed 
at the early phase, sustained by a putative continuous signal during the late phase, or both. If the former is true, 
the early cytokine environment might have a role in programming maintenance. In our experimental system, 
different profiles of type I IFN and IFN-γ secretion were observed among the groups during the early phase. In 
fact, the role of type I IFN and IFN-γ in CD4+ T cell homeostasis is controversial depending on the conditions. A 
recent review describes important roles of type I IFN for the survival of CD4+ T cells depending on the context 
of TCR stimulation and the mode of infection33. A direct requirement of type I IFN for the survival of CD4+ T 
cells is not observed in bacterial immunization34. Similarly, direct IFN-γ signaling is reported to enhance CD4+ 
T cell memory in a virus infection model35, whereas the opposite effect is reported for CD8+ T cells in a peptide 
immunization model36. Therefore, further studies are required to determine the complex effects of type I IFN and 
IFN-γ on the expansion, differentiation, and maintenance of CD4+ T cells.
Upon several rounds of boosting, multi-functional antigen-specific CD4+ T cells that were thought to be 
amplified and further matured from the remaining memory CD4+ T cells were more abundant in mice immu-
nized with OVA and L-pampo compared to the other groups. The multi-cytokine-producing CD4+ T cells are 
critical for clearing or reducing low levels of viruses in response to infection with various types of viruses, includ-
ing HIV, influenza virus, Epstein-Barr virus (EBV), varicella-zoster virus (VZV), or cytomegalovirus (CMV), and 
correlating protection against a second challenge with L. major37. Furthermore, a higher quality of CD8+ T cells 
producing multi-cytokines was observed in the L-pampo group compared to those in the other groups despite a 
similar number of antigen-specific CD8+ T cells in the polyI:C group. Therefore, L-pampo enhances the quality 
of antigen-specific T cells upon boosting.
When L-pampo is used for clinical application, the toxicity issue should be carefully considered as a high-dose 
of pathogen-associated molecular patterns (PAMPs) could induce cytokinemia. Indeed, it is reported that TLR3 
mediates the acute inflammation of skin after exposure to ultraviolet B (UVB) radiation38. Recently, phosphoro-
thioate ODN-guided dsRNA (sODN-dsRNA), which triggers selectively TLR3 with no ability to activate RIG-I/
MDA5, is reported to be less toxic because of its capability to induce less pro-inflammatory cytokines but mount 
comparable anti-tumor cellular immunity compared to polyI:C that triggers both TLR3 and RIG-I/MDA5 path-
ways39. If we need a higher dose of polyI:C which is efficacious but could be toxic, TLR3-selective ligand seems to 
be a good alternative to reduce the toxicity.
Similar to our observation on the synergy between TLR ligands as an adjuvant, some studies have also shown 
that combinations of TLR ligands can provide advantages as vaccine adjuvants. The combinations provided more 
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protection against pathogens than the constituents given individually. When rhesus monkeys were vaccinated 
with inactivated pandemic influenza virus mixed with MPL (TLR4 ligand) and R837 (TLR7 ligand), a robust 
humoral immune response was synergistically induced5. In this system, adjuvants activating three TLR ligands 
via MPL and R848 (TLR7 and TLR8 ligands, respectively) induced a greater antibody response, even greater than 
what is required for protection after a boost5. Indeed, the triple combination of polyI:C, MALP2 (TLR2/6 ligand), 
and CpG (TLR9 ligand) vaccinated with the HIV envelope peptide showed a remarkable protection against HIV 
envelope protein-expressing VV compared to that observed for the dual combinations6. In this context, our study 
provides an efficacious TLR ligand combination, composed of the TLR1/2 and TLR3 ligands, that synergistically 
enhances the quality of antibodies and T cells as well as the quantity of antibodies and CD4+ T cells, which have 
implications for efficacious vaccine development.
Methods
Mice. C57BL/6 (000664), CD45.1 (002014), OT-II (004194), and OT-I (003831) mice were purchased from 
the Jackson Laboratory. For the identification of transferred cells within hosts, OT-II and OT-I mice were bred 
onto homo- or heterozygous CD45.1 allele backgrounds. All of the animal experiments were conducted in 
accordance with the Korean Food and Drug Administration guidelines. Protocols were reviewed and approved 
by the Institutional Animal Care and Use Committee (IACUC) of the Yonsei Laboratory Animal Research Center 
(YLARC) at Yonsei University.
Adoptive cell transfers. Congenically marked (CD45.1) splenic CD4+ T cells specific to the OVA323–339 
epitope of OVA from naive OT-II transgenic mice were isolated using the MagnisortTM Mouse CD4 T Cell 
Enrichment Kit (eBioscience), and 5 × 105 of the isolated OT-II cells were transferred intravenously into naïve 
B6 (CD45.2) mice before immunization. In some experiments, splenic CD8+ T cells specific to the OVA257–264 
epitope of OVA from naïve OT-I transgenic mice were isolated separately alongside the OT-II cells, and 5 × 105 of 
the isolated OT-I/OT-II cells from each mouse (total 1 × 106/mouse) were intravenously co-transferred into naïve 
B6 (CD45.2) mice before immunization.
Immunization. The preparation of L-HBsAg and the formulation of L-pampo (Korean patent 10-0900837), 
which is a mixture of pam3csk and polyI:C, was conducted as previously described16. Briefly, the entire coding 
region of the HBV envelope gene (pre-S1-pre-S2-S) was ligated into the pMSG vector (Korean patent 10-2000-
0043996) and transfected into CHO cells to obtain high amounts of L-HBsAg, including L, M, and S proteins. 
L-HBsAg was purified from the culture medium of the recombinant CHO cell line that showed the highest 
expression level of L-HBsAg16.
Each B6 mouse was immunized intraperitoneally with 100 μ g of OVA or 40 μ g of L-HBsAg, in combination 
with 500 μ g of alum (Alhydrogel; Brenntag Biosector), 125 μ g of pam3csk (C-tri), 100 μ g of polyI:C (Yamasa), or 
L-pampo as adjuvants in 400 μ l of buffer containing 150 mM NaCl and 10 mM sodium phosphate (pH 6.9).
In vivo cytokine secretion. After immunization, the supernatants from homogenized spleens and serum 
were collected at the indicated time points. A multiplex analysis of IFN-γ , IFN-α , TNF-α , and IL-6 was assayed 
using Flowcytomix (eBioscience) according to the manufacturer’s instructions. The samples were read using a 
FACS Canto II (BD) and analyzed using Flowcytomix Pro software (eBioscience).
Flow cytometry. Single-cell suspensions were prepared by gentle mechanical disruption of spleens, followed 
by lysis with ACK lysis buffer to remove RBCs, then surface-stained with anti-CD4 (RM4-5), CD8 (53–6.7), 
CD45.1 (A20), CD44 (IM7), PD-1 (RMP1-30), B220 (RA3-6B2), CD19 (ebio1D3), CD95 (Jo2), or T cell– and 
B cell–activation antigen (GL7) antibodies (directly conjugated by FITC, PE, PerCP-Cy5.5, PE-Cy7, APC, 
BV421, or BV605, respectively). Dead cells were excluded by using LIVE/DEAD Fixable Violet Dead Cell Stain 
(Life Technologies). A three-step CXCR5 staining was performed as previously described using puri-
fied rat anti-mouse CXCR5 (BD), a secondary biotin-conjugated Affinipure Goat anti-rat IgG (Jackson 
ImmunoResearch), and finally with streptavidin-APC (Invitrogen) or streptavidin-BV605 (Bioclone)40. For Bcl6 
(K112-91) staining, the cells were stained for surface antigens, followed by permeabilization, fixation, and stain-
ing using the Foxp3 Permeabilization/Fixation Kit and Protocol (eBioscience). Intracellular cytokine staining of 
IFN-γ (XMG1.2), TNF-α (MP6-XT22), and IL-2 (JES6-5H4) was performed using the Cytofix/Cytoperm Kit 
(BD Pharmingen) according to the manufacturer’s instruction. All of the staining antibodies were purchased 
from BD, eBioscience, or BioLegend. Flow cytometric data were collected on a FACS Canto II (BD) and analyzed 
using the FlowJo software (TreeStar).
In vivo DC generation and cell isolation. Splenic dendritic cells were expanded in the mice as previ-
ously described41. Briefly, B6 mice were injected subcutaneously with 5 × 105 Flt3L-secreting B16F10 melanocytes 
in Hank’s Balanced Saline Solution (HBSS). After 2 weeks, the spleens were collected, digested by collagenase, 
and filtered through a mesh before magnetic isolation. Single-cell suspensions of the prepared splenocytes were 
pre-enriched by magnetic depletion of B and T cells with microbead-conjugated antibodies to CD19 (Miltenyi 
Biotec) and CD90.2 (Miltenyi Biotec), respectively. The depleted cells were then subjected to magnetic selection 
of CD11c+ conventional dendritic cells using CD11c microbeads (Miltenyi Biotec) to > 90% purity.
Cell culture. The mouse macrophage cells and RAW 264.7 cells were cultured in high glucose Dulbecco’s 
Modified Eagle’s medium (DMEM; Welgene) supplemented with 5% fetal bovine serum and 1% antibiotics. The 
cell line was maintained at 37 °C under an atmosphere of 5% CO2.
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Cytokine ELISA assay. Splenocytes (1.5 × 106cells/100 μ l) from immunized mice were stimulated with 
antigen (OVA (100 μ g/ml) or L-HBs (40 μ g/ml)) or OVA323–339 peptide and OVA257–264 peptides for 24–48 h, and 
non-stimulated splenocytes were used as a negative control. After stimulation, the cytokines in the supernatants 
were measured by an ELISA assay according to the manufacturer’s protocol (BD).
Enzyme-linked immunospot (ELISpot) assay. The mouse IFN-γ /IL-4 ELISPOT assay (Mabtech) 
was performed according to the manufacturer’s protocol. Briefly, splenocytes (1 × 106 cells/100 μ l) were added 
to a 96-well ELISPOT plate pre-coated with anti-mouse monoclonal IFN-γ or IL-4 antibodies. The cells were 
incubated with antigens (OVA (100 μ g/ml), L-HBs (40 μ g/ml)), OVA323–339 peptides, and OVA257–264 pep-
tides or medium alone for 24–48 h. After stimulation, the wells were washed and incubated with biotinylated 
anti-mouse IFN-γ or IL-4 antibody for 2 h at RT. Subsequently, the wells were washed and incubated with 
streptavidin-horseradish peroxidase (HRP) for 1 h. Spot-forming cells (SFC)s were developed with TMB sub-
strate and counted using the AELVIS ELISPOT Reader.
Western blot analysis. The cells were lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton 
X-100, 0.5% sodium deoxycholate and 0.1% SDS) supplemented with protease and phosphatase inhibitors for 
30 min on ice. The cell lysates were cleared by centrifugation. The proteins were resolved by SDS-PAGE and trans-
ferred to a nitrocellulose membrane (Whatman/GE). The membranes were probed with antibodies. The following 
were used for western blotting: antiphospho-IRF3 (Cell Signaling), anti-IRF3 (Cell Signaling), antiphospho-IRF7 
(Cell Signaling), anti-IRF7 (Cell Signaling), antiphospho-TBK1 (Cell Signaling), anti-TBK1 (Santa Cruz), 
antiphospho-IkBa (Cell Signaling), anti-IkBa (Cell Signaling), antiphospho-p38 (Cell Signaling), anti-p38 
(Cell Signaling), antiphospho-JNK (Santa Cruz), anti-JNK (Santa Cruz), antiphospho-ERK (Santa Cruz), and 
anti-actin (Santa Cruz). Visualization was performed on film using ECL Plus (GE Healthcare).
Antibody titer analysis. Mouse serum was obtained from the mouse eyes. The antibody titers were deter-
mined using a standard ELISA protocol. Briefly, 96-well microplates were coated with Ag (OVA or L-HBs) at a 
concentration of 1 μ g/ml and blocked with bovine serum albumin (1%) for 1 h. The plates were incubated in a 
37 °C incubator. After the microplates were washed, diluted serum was added to each well, and the plates were 
incubated at 37 °C for 2 h. Then, HRP-conjugated anti-mouse IgG (KPL) was added as a secondary antibody, 
and the plates were incubated at 37 °C for 1 h. After washing, a color-developing agent (tetramethylbenzidine 
[TMB]-peroxidase solution; KPL) was added, and the mixture was incubated at room temperature for 5 min. 
Then, the optical density (OD) of each well was measured at 450 nm using an automatic ELISA plate reader. To 
determine the titers of the antibody isotypes, a mouse monoclonal antibody isotyping reagent was used for IgG1, 
IgG2a, IgG2b (Sigma), and IgG2c (SouthernBiotech).
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